Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 5/20 | 0.50 |
| ▸ | CA2 | P00918 | 5/20 | 0.50 |
| ▸ | CA12 | O43570 | 4/20 | 0.50 |
| ▸ | CA9 | Q16790 | 4/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.50 |
| ▸ | MMP2 | P08253 | 4/20 | 0.50 |
| ▸ | CA3 | P07451 | 3/20 | 0.50 |
| ▸ | CA4 | P22748 | 3/20 | 0.50 |
| ▸ | CA6 | P23280 | 3/20 | 0.50 |
| ▸ | CA5A | P35218 | 3/20 | 0.50 |
| ▸ | CA7 | P43166 | 3/20 | 0.50 |
| ▸ | CA13 | Q8N1Q1 | 3/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.50 |
| ▸ | MMP9 | P14780 | 3/20 | 0.50 |
| ▸ | MMP8 | P22894 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26836 | 0.93 | ALDH1A1 (0.62) | ALDH1A1CYP3A4MAPK1LMNACA1 | |
| SCHEMBL8746207 | 0.93 | ALDH1A1 (0.62) | ALDH1A1CYP3A4MAPK1LMNACA1 | |
| SCHEMBL8477054 | 0.93 | ALDH1A1 (0.62) | ALDH1A1CYP3A4MAPK1LMNACA1 | |
| SCHEMBL4452026 | 0.92 | CYP1A2 (0.60) | ALDH1A1CYP3A4MAPK1CA1CA2 | |
| Water SCHEMBL338049 | 0.90 | ALDH1A1 (0.59) | ALDH1A1CYP3A4MAPK1LMNACA1 | |
| SCHEMBL8714706 | 0.90 | ALDH1A1 (0.59) | ALDH1A1CYP3A4MAPK1LMNACA1 | |
| SCHEMBL6913648 | 0.90 | ALDH1A1 (0.59) | ALDH1A1CYP3A4MAPK1LMNACA1 | |
| SCHEMBL125764 | 0.90 | ALDH1A1 (0.59) | ALDH1A1CYP3A4MAPK1LMNACA1 | |
| Ammonia Solution, Strong SCHEMBL11740925 | 0.90 | ALDH1A1 (0.59) | ALDH1A1CYP3A4MAPK1LMNACA1 | |
| SCHEMBL8720147 | 0.90 | ALDH1A1 (0.59) | ALDH1A1CYP3A4MAPK1LMNACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200323986-A1 | HYDROPHOBIC ARENESULFONATE SALTS | THERACAINE LLC | 2020-10-15 | — | — | US | claimed |
| EP-3703686-A1 | HYDROPHOBIC ARENESULFONATE SALTS | Theracaine LLC (US) | 2020-09-09 | — | — | EP | claimed |
| US-6849635-B2 | Sulfonamides | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-01 | — | — | US | claimed |
| EP-1455777-A1 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | SMITHKLINE BEECHAM PLC (GB) | 2004-09-15 | — | — | EP | claimed |
| US-20040152893-A1 | Sulfonamides | SMITHKLINE BEECHAM CORPORATION | 2004-08-05 | — | — | US | claimed |
| WO-2003055478-A1 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-07-10 | — | — | WO | claimed |
| EP-3145944-B1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2021-05-05 | — | — | EP | disclosed |
| EP-3145944-B1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2021-05-05 | — | — | EP | disclosed |
| US-20200323986-A1 | HYDROPHOBIC ARENESULFONATE SALTS | THERACAINE LLC | 2020-10-15 | — | — | US | disclosed |
| US-10392422-B2 | Macrocyclic broad spectrum antibiotics | RQX PHARMACEUTICALS, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| US-10392422-B2 | Macrocyclic broad spectrum antibiotics | RQX PHARMACEUTICALS, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| US-10351595-B2 | — | — | 2019-07-16 | — | — | US | disclosed |
| US-10351595-B2 | — | — | 2019-07-16 | — | — | US | disclosed |
| WO-1999042443-A1 | SULFONYLAMINO DERIVATIVES WHICH INHIBIT MATRIX-DEGRADING METALLOPROTEINASES | NOVARTIS AG (CH) | 1999-08-26 | — | — | WO | disclosed |
| EP-0844877-A1 | USE OF OXIDO-SQUALENE CYCLASE INHIBITORS TO LOWER BLOOD CHOLESTEROL | ZENECA LIMITED (GB) | 1998-06-03 | — | — | EP | disclosed |
| EP-0783500-A1 | AMINOHETEROCYCLIC DERIVATIVES AS ANTITHROMBOTIC OR ANTICOAGULANT AGENTS | ZENECA LIMITED (GB) | 1997-07-16 | — | — | EP | disclosed |
| WO-1997006802-A1 | USE OF OXIDO-SQUALENE CYCLASE INHIBITORS TO LOWER BLOOD CHOLESTEROL | ZENECA LIMITED (GB) | 1997-02-27 | — | — | WO | disclosed |
| WO-1996010022-A1 | AMINOHETEROCYCLIC DERIVATIVES AS ANTITHROMBOTIC OR ANTICOAGULANT AGENTS | ZENECA LIMITED (GB) | 1996-04-04 | — | — | WO | disclosed |
| EP-0395883-B1 | Mixtures of poly(arylene sulfides) with sulfonic end groups or their derivates with poly(arylene sulfides, and their use | BAYER AG (DE) | 1995-05-03 | — | — | EP | disclosed |
| US-5068312-A | Molding materials formed by reacting dihalogen compounds with a sulfur donor in a solvent | BAYER AKTIENGESELLSCHAFT (DE) | 1991-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10351595-B2 | — | MRPL21, PRSS1, PEPD | ALDH1A1 2620/4885CYP3A4 4246/4885MAPK1 664/4885 |
| US-10392422-B2 | Macrocyclic broad spectrum antibiotics | MRPL21, PEPD, CTSC | ALDH1A1 2364/4885CYP3A4 3437/4885MAPK1 396/4885 |
| US-20200323986-A1 | HYDROPHOBIC ARENESULFONATE SALTS | ARSA, SLC26A3, ABCB11 | ALDH1A1 928/4885CYP3A4 2231/4885MAPK1 3609/4885 |
| US-20040152893-A1 | Sulfonamides | UTS2R, PRSS2, STS | ALDH1A1 3733/4885CYP3A4 2591/4885MAPK1 4829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.